Novo Nordisk proposed to acquire the Belgian biopharmaceutical company Ablynx NV
The Danish pharmaceutical company Novo Nordisk proposed to acquire the Belgian biopharmaceutical company Ablynx NV. The offer is for 28 EUR per share in cash with potential cash payments of up to €2.50 per share based on progress in upcoming medicine trials. This represents a total equity value of about 2.6 billion EUR.
The merger will combine the Novo Nordisk’s regulatory, scientific and commercial experience with Ablynx’s strong medical teams. This will optimize the development of global marketing and drug development for rare blood diseases Caplacizumab.
“The proposed transaction with Ablynx represents a compelling opportunity for both companies and is in the best interests of all of ABlynx’s stakeholders”, said the Novo Nordisk chief executive, Lars Fruergaard Jorgensen. “Novo Nordisk and Ablynx share a common focus on innovation-driven, patient-centric R&D. Novo Nordisk intends to use its full suite of regulatory, scientific and marketing expertise to complement the existing strong management and medical team at Ablynx in order to optimise the development and global commercialisation of caplacizumab for the benefit of patients suffering from aTTP”, added he.
Ablynx’s main asset is caplacizumab, a treatment for the rare bleeding disorder acquired Thombotic Thrombocytopenic Purpura (aTTP), and Novo Nordisk said a deal offered a compelling opportunity to combine caplacizumab with its own existing haematology business.
The approach comes at a time of renewed interest by large drugmakers in acquiring smaller biotech companies to boost their product portfolios.